Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia

Shellaina J.V. Gordon(The University of Melbourne), Mark A. Dawson(The University of Melbourne), Jeffrey D. White(Stony Brook School), Kathy Knezevic(Peter MacCallum Cancer Centre), Yih-Chih Chan(The University of Melbourne), Jakub Horvath(The University of Melbourne), Scott A. Armstrong(Courant Institute of Mathematical Sciences), Daniela V. Wenge(Dana-Farber Cancer Institute), Brendon J. Monahan(Monash University), Dane Vassiliadis(The University of Melbourne), Michelle A. Camerino(Monash University), Wallace Bourgeois(NYU Langone Health), Shikhar Sharma(Pfizer (United States)), John D. Lapek(University of Rochester Medicine), Ian P. Street(Unknown), Xinmeng Jasmine Mu(Pfizer (United States)), Enid Y.N. Lam(The University of Melbourne), Jesse J. Balic(Hudson Institute of Medical Research), Thomas A. Paul(Pfizer (United States)), Henrietta Holze(The University of Melbourne), Ylva E. Bozikis(Monash University), Paul A. Stupple(Monash University), Andrea Gillespie(National Institutes of Health), Florian Perner(Medizinische Hochschule Hannover), Sean Uryu(Pfizer (United States)), Elanor N. Wainwright(Peter MacCallum Cancer Centre), Benjamin J. Blyth(Peter MacCallum Cancer Centre), Jelena Petrovic(Cancer Research Institute), Joan Cao(Pfizer (United States)), Katie Fennell(Peter MacCallum Cancer Centre), Tabea Klaus(Medizinische Hochschule Hannover), Laura MacPherson(Natural Resources Canada)
bioRxiv (Cold Spring Harbor Laboratory)
December 12, 2024
Cited by 5


Related Papers